217500-96-4

Basic information

• Product Name: Tulathromycin A
• Synonyms: TULATHROMYCIN A;(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-Dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-a-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one;Unii-897A3kn7ap;(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-Dideoxy-3-C-Methyl-3-O-Methyl-4-C-[(propylaMino)Methyl]-α-L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexaMethyl-11-[[3,4,6-trideoxy-3-(diMethylaMino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one;CP 472295;Draxxin;Tulathromycin A, >=95%;Tulathrmycin A
• CAS NO: 217500-96-4
• Molecular Formula: C41H79N3O12
• Molecular Weight: 806.084
• EINECS: 1806241-263-5
• Product Categories: Carbohydrates & Derivatives;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;API
• Mol File: 217500-96-4.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 853.8±65.0 °C(Predicted)
• Appearance: /
• Density: 1.17
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 13.19±0.70(Predicted)
• CAS DataBase Reference: Tulathromycin A(CAS DataBase Reference)
• NIST Chemistry Reference: Tulathromycin A(217500-96-4)
• EPA Substance Registry System: Tulathromycin A(217500-96-4)

Safety Data

• Hazardous Substances Data: 217500-96-4(Hazardous Substances Data)

Usage

Description

Tulathromycin A is a triamide antibiotic belonging to the macrolide class, characterized by its 15-membered macrolide structure and three charged nitro groups. It exists as a balanced mixture of two isomers and is known for its antimicrobial properties. Tulathromycin A is an aminoglycoside and appears as a white solid.

Uses

Used in Veterinary Medicine:
Tulathromycin A is used as a therapeutic agent for the treatment of respiratory diseases in cattle and pigs. It is effective against various bacterial pathogens, including Haemophilus somnus, Mycoplasma bovis, Fusarium necrophorum, Fusarium oxysporum, Actinobacillus pleuropneumoniae, Bacteroides multilocularis, Bordetella bronchiseptica, Mycoplasma pneumoniae, and Haemophilus parasiticus.
Used in Cattle:
Tulathromycin A is used as a treatment for rinderpest caused by Haemolytic rinderpest, polyvalent rinderpest, and infections caused by Mycoplasma bovis. It is also utilized to prevent infections in high-risk calves and to treat bovine foot rot associated with Fusarium necrophorum and Fusarium oxysporum. Additionally, it is effective in treating bovine infectious keratoconjunctivitis (Mycobacterium bovis).
Used in Pigs:
In pigs, Tulathromycin A is used to control and treat Swine Respiratory Disease (SRD) associated with Actinobacillus pleuropneumoniae, Bacteroides multilocularis, Bordetella bronchiseptica, Mycoplasma pneumoniae, and Haemophilus parasiticus. It has also been used to treat lung abscesses in pigs.

Upstream product

• 107-10-8 propylamine 
• 217649-77-9 carbonic acid benzyl ester 4-dimethylamino-2-[2-ethyl-3,4,10-trihydroxy-13-(8-methoxy-4,8-dimethyl-1,5-dioxa-spiro[2.5]oct-6-yloxy)-3,5,8,10,12,14-hexamethyl-15-oxo-1-oxa-6-aza-cyclopentadec-11-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester 
• 111321-02-9 erythromycin A 9-(E)-oxime 
• 76801-85-9 9-Deoxo-9a-aza-9a-homoerythromycin A 
• 352032-78-1 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-[(phenylmethoxy)carbonyl]-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one 

Relevant articles and documents

Preparation method of tulathromycin

The invention relates to a synthetic method of tulathromycin. Under the action of illumination and a specific catalytic system, rapid, efficient and pollution-free synthesis of tulathromycin is realized. Compared with the existing synthetic method, the synthetic method provided by the invention is simple to operate, mild in condition and capable of meeting the requirement of large-scale industrial production.

Preparation method for tulathromycin

The invention provides a preparation method for tulathromycin, and belongs to the technical field of drug synthesis. The method comprises the following steps: mainly by using dihydroerythromycin (9-deoxo-9a-aza-9a-homoerythromycin A) as a raw material, performing a hydroxyl protection reaction, performing a selective oxidation reaction of 4'-hydroxyl to generate a ketone, performing an epoxidationreaction to generate an epoxide, performing deprotection, and performing a ring-opening reaction to introduce n-propylamine to generate the target product tulathromycin. In the method, an oxidizing agent for the selective oxidation reaction of the 4'-hydroxyl is hydrogen peroxide or a Dess-Martin periodinane, so that the method avoids the use of equivalent or excessive amounts of a high-valent metal oxidizing agent, has low costs and mild reaction conditions, and improves the yield and purity of the product.

Preparation method of tulathromycin

The invention provides a preparation method of tulathromycin, and belongs to the field of pharmaceutical chemicals. The method comprises the following steps of: reacting azithromycin serving as a rawmaterial with phenyl chloroformate to protect hydroxyl to obtain protected nitrogen azithromycin, oxidizing the hydroxyl into a ketone group by oxidation, epoxidizing, deprotecting, and reacting withn-propylamine to obtain tulathromycin. The product produced by the method has the characteristics of high purity, high yield, low cost, simple operation and stable process.